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with and, if necessary, treated for knee cartilage defects by
arthroscopy at one of seven centres in Germany. Patients were
assigned to the initial operation (IO) group if the study physician
was able to conﬁrm that the study arthroscopy was the patient’s
ﬁrst surgical procedure ever on that particular knee. All other
patients were assigned to the re-operation (RO) group. Patients
were interviewed on their postsurgical outcome with two disease-
speciﬁc (Tegner Scale and IKDC Subjective Knee Form [IKDC-
SKF] including a retrospective assessment of their pre-surgical
health state) and a generic instrument (SF-36). RESULTS: Data
from a total of 1708 patients were included in the ﬁnal analysis.
Of these, 1070 were assigned to the initial operation (IO) group
(61% men, 49  15 years; 39% women, 52  14 years) and 638
were assigned to the re-operation (RO) group (64% men,
44  13 years; 36% women, 47  14 years). Participants expe-
rienced a level reduction of 1.5 (IO) and 2.5 (RO) resp. with the
Tegner scale. Patients reported a functional knee status measured
by the IKDC-SKF of 64% to 84% dependent on the surgical
procedure performed. Signiﬁcantly lower scores than the general
population were observed with the SF-36 for the physical func-
tioning, role-physical, and role-emotional scales, as well as for
the physical health summary measure. The strongest limitations
in the overall study population compared to the general popula-
tion were seen on the physical functioning, role-physical, and
role-emotional dimensions. In all three instruments the RO
group experienced more severe reductions in quality of life.
CONCLUSIONS: Despite extensive treatments participants
experienced lasting reductions in quality of life. Surgical proce-
dures differ in their long-term outcome. Longer history of inter-
ventions decrease the treatment related outcomes.
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OBJECTIVES: Total hip and knee replacement are very common
procedures. Both of them improve function, pain and health
related quality of life (HRQoL). The aim of this study was to
compare baseline scores and improvements at one year inHRQoL
according to the operated joint. METHODS: This prospective
observational study was carried out in 15 hospitals with consecu-
tive patients. All included patients fulﬁlled 3 HRQoL question-
naires at two times, 1 month pre surgery and 12 months post
surgery. There were 2 generic questionnaires; EQ-5D and SF-12
and one speciﬁc, the WOMAC. We compare the baseline scores
and improvements at one year by mean of Student’s t test.
RESULTS: The analysis was performed over 864 patients who
fulﬁlled the included questionnaires. There were 355 hips and 509
knees. Mean age (mean  s.d.) was not different between hip
(63.5  19.9) and knee (64.3  23.8) patients. At baseline,
patients who were waiting for hip replacement had only worse
score in the function dimension of WOMAC (64.8  16.6 vs
61.1  17.6) (p = 0.002). According to the improvements at one
year, there were statistically signiﬁcant differences in all EQ-5D
and WOMAC dimensions. The patients in the hip group experi-
enced higher improvements in EQ-5D index (p = 0.005), VAS
(p = 0.005), WOMAC pain (p < 0.001), function (p = 0.001) and
stiffness (p < 0.001). There were no statistically differences in the
improvements measured by SF-12. CONCLUSIONS: In the light
of these datawe can conclude that at baseline patients have similar
HRQoL scores, while at 1 year those who have undergone hip
replacement experienced a higher improvement in the affected
dimensions. In addition, the generic questionnaire SF-12 does not
seem to capture the changes in HRQoL in these patients.
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OBJECTIVES: To evaluate the effect of golimumab (GLM) on
self-reported productivity in rheumatoid arthritis (RA) patients.
METHODS:The effect of GLMon self-reported productivity was
evaluated in threemulticenter, randomized, double-blind, placebo
(PBO)-controlled studies in RA patients. Data from patients
receiving GLM or PBO with or without methotrexate (MTX) are
presented. The trials evaluated different patient populations and
included patients naïve to MTX (GO-BEFORE), patients with
active RA despite MTX (GO-FORWARD), and patients previ-
ously treated with anti-TNF-alpha agent(s) (GO-AFTER). GLM
subcutaneous injections of 50 mg or 100 mg were administered
q4wks. Atwks0 and 24, patientswere asked to indicate howmuch
their disease affected their productivity at work, school or at home
in the past 4wks using a 0 (did not affect productivity at all) to 10
(affected productivity very much) VAS scale. A negative mean
change from baseline is an improvement in self-reported produc-
tivity. An ANOVA on van der Waerden normal scores was per-
formed for between-group comparisons. RESULTS: In each of
the trials mean baseline scores for self-reported productivity
were comparable between groups (ranges were 6.3–6.4[GO-
BEFORE] 5.4–5.7[GO-FORWARD], 6.2–6.7[GO-AFTER]). In
GO-FORWARD, the mean(SD) improvements in self-reported
productivity were signiﬁcantly greater in the GLM50 and 100 mg
+ MTX groups compared with PBO + MTX at wk24 (-1.97 
3.12, -2.00  2.53, and -0.45  2.98, respectively, p < 0.001).
In GO-AFTER, the mean(SD) improvements in self-reported
productivity were signiﬁcantly greater in the GLM50 and 100 mg
groups compared with PBO at wk24 (-1.77  2.90, -2.10 
2.92, and -0.52  2.79, respectively, p < 0.001). In GO-
BEFORE, numerical improvements in self-reported productivity
were observed in the GLM 50 and 100 mg + MTX groups
(-2.48  2.94 and -2.90  2.80, respectively); these improve-
ments were not signiﬁcantly different from PBO + MTX
(-2.27  3.02). CONCLUSIONS: In two studies, GLM resulted
in signiﬁcant improvements in self-reported productivity. In the
third trial, GLM resulted in trends towards improvement in
self-reported productivity compared with PBO + MTX.
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OBJECTIVES: To evaluate welfare changes in individuals using
balloon kyphoplasty (BKP) for the treatment of vertebral body
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compression fractures in Spain. METHODS: Two alternative
models will be introduced here. One standard contingent valua-
tion model (CV), where mean values for willingness to pay
(WTP) for the treatment with BKP are obtained through a survey
including patients with primary osteoporosis. A new quality of
life adjusted wages model (QAW) is also introduced here. The
main assumption of this model is that a disease acts on individu-
als as a tax, where wages are deﬂected here by a quality of life
index (EuroQol 5-D) in the same way as a proportional income
tax. The burden of disease is given by this model in terms of an
equivalent variation or welfare changes in monetary terms. The
model avoids different kind of biases introduced in many times
by the CV approach and is a faster and more rigorous tool to ﬁnd
welfare changes determined by diseases and their medical treat-
ments. RESULTS: A sample of 168 individuals who had been
asked about their WTP for BKP was used to develop the CV
model. A mean value for WTP of €3909 is revealed by the
sample. A sample of 300 patients 21 years of age or older and
both genders coming from a clinical trial designed by Kyphon,
was used to develop QAW model, here is that BKP determines in
the ﬁrst month a yearly welfare gain of €2665, increased to
€3311 after 12 months. CONCLUSIONS: The results using CV
models and QAW model are similar in the ﬁrst year of life. It can
be explained through a temporal downward bias introduced by
WTP responses that means that a patient doesn’t include in his
personal WTP an estimation of his life expectancy.
MUSCULAR-SKELETAL DISORDERS—Health Care Use
& Policy Studies
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OBJECTIVES: Evidence-based guidelines recommend treatment
for postmenopausal women with osteoporosis to prevent frac-
tures. The study aims at determining since when this was known
and whether the utilization of bisphosphonates in Germany from
this point onward was adequate and to what extent health gains
might have been foregone due to a limited use of bisphosphonates.
METHODS: To determine since when the beneﬁcial effect (pre-
vention of fractures) was known, cumulative meta-analyses of
randomized controlled trials derived from systematic reviews
were conducted. The evidence-base was considered as established,
when a signiﬁcant (5%-level) reduction of fractures was observed
in trial populations combined inmeta-analysis compared to thera-
pies without bisphosphonates. Utilization ﬁgures for bisphospho-
nates and epidemiological estimates where taken from published
sources. RESULTS: The hip/femur fracture risk was signiﬁcantly
lower if treatment included bisphosphonates compared to treat-
ment without bisphosphonates (RR 0.62; 95%-CI 0.40–0.97 / RR
0.45; 95%-CI 0.23–0.90). In principal, this was known since
1995/1996. Utilization of bisphosphonates in 1996 was sufﬁcient
for the continuous treatment of about 8,200 patients (440,000
patients in 2006). About 1.6 to 1.9million patients annuallymight
have beneﬁtted from treatment. About 22,800 fractures might
thus have been avoided, had all patients with potential beneﬁt
continuously received bisphosphonates since 1996/1997. CON-
CLUSIONS: The delay in the wider use of bisphosphonates for
osteoporosis treatment has resulted in a considerable loss of
potential health gains in terms of avoided fractures. An arguable
lack of evidence for the expected beneﬁt from bisphosphonate
therapy does not sufﬁciently explain this ﬁnding. Other factors
(e.g. cost considerations) might have contributed to this result.
Limitations of the present analysis are primarily associated with
uncertainties of epidemiological estimates and the application of
study results to the entire patient population.
PMS68
ANTI-TUMOUR NECROSIS FACTOR-&ALPHA; INHIBITOR
DOSE CHANGES IN RHEUMATOID ARTHRITIS PATIENTS IN A
PROSPECTIVE PATIENT REGISTRY SETTING
Kievit W1,Tatt ID2,Van Riel P1
1Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands, 2F.Hoffmann-La Roche Ltd, Basel, Switzerland
OBJECTIVES: Real-world data on long-term dosing patterns
in ﬁrst time anti-TNFa inhibitor treated rheumatoid arthritis
patients is lacking. Such data are important for the calculation
of treatment cost, especially for products where the label
allows for varying doses and frequency of administrations.
METHODS: The Dutch Rheumatoid Arthritis Monitoring
(DREAM) project is a longitudinal, multi-centre patient register
monitoring biologic DMARD usage in clinical practice since
February 2003. Patients meeting the Dutch reimbursement
criteria (DAS28 > 3.2, inadequate response to 2 DMARDs
including methotrexate, no prior bDMARDs) were assessed at
three-month intervals for 48 months. Dosing was determined by
the attending rheumatologist guided by the recommended
labelled doses (adalimumab 40 mg every other week, etanercept
25 mg twice weekly, inﬂiximab 3 mg/kg at week 0, 2, 4, 8 and
every 8 weeks thereafter). Mean dose was calculated based on
the actual dose prescribed at each visit and the change over time
evaluated for each anti-TNFa. RESULTS: The mean baseline
doses for adalimumab (N = 374), etanercept (N = 432) and
inﬂiximab (N = 325) were 39.9 mg/two weeks, 24.2 mg twice
weekly, and 3.4 mg/kg per eight weeks. Mean baseline DAS28
and HAQ ranged from 5.2–5.4 and 1.3–1.4, respectively.
Nearly one-third of inﬂiximab patients were prescribed greater
than the labelled dose at baseline (32%, N = 105) compared to
2.5% and 0.2% for adalimumab and etanercept. At 12, 24, and
48 months follow-up, mean doses were: adalimumab, 41.5,
43.3, and 45.7 mg/two weeks (42 months); etanercept, 24.0,
24.9, and 23.9 mg twice per week (45 months); inﬂiximab, 4.3,
4.9, and 4.9 mg/kg/every eight weeks (48 months). Mean doses
in inﬂiximab patients prescribed greater than the recommended
labelled dose at baseline were 4.7, 5.2, and 5.6 mg/kg at the
same follow-up intervals. CONCLUSIONS: Longitudinal
patient registry data from The Netherlands show a marked and
continued dose escalation in RA patients prescribed inﬂiximab
as a ﬁrst-line anti-TNFa when compared to either adalimumab
or etanercept.
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OBJECTIVES: To determine the co-morbidity and direct cost
inﬂuence in patients with osteoporosis in a Spanish population
setting in under usual medical practice. METHODS: We per-
formed a transversal retrospective study realized beginning from
registers of subjects older than 44 years appertaining to seven
centers of primary care (year 2,006). A control group without
osteoporosis was formed. Main measures: general (age, gender),
general co-morbidities and speciﬁc (ICPC-2), Charlson index
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